Key result
The AAV inverted terminal repeat retains unanswered questions regarding the functions attributable to its terminal 125 nucleotides despite its sequence being known for 40 years.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Highlights gaps in AAV vector design for cardiac gene therapy; leaves open the functional roles of ITR terminal sequences for targeted investigation.
Although the sequence of the AAV inverted terminal repeat has been known for 40 years, there are still unanswered questions about functions attributable to the terminal 125 nucleotides.
No takes yet. Share an insight, caveat, or question.
Kenneth I. Berns (2020) studied this question. The AAV inverted terminal repeat retains unanswered questions regarding the functions attributable to its terminal 125 nucleotides despite its sequence being known for 40 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: